Home » Stocks » NTEC

Intec Pharma Ltd. (NTEC)

Stock Price: $3.25 USD 0.21 (6.91%)
Updated November 27, 1:00 PM EST - Market closed
After-hours: $3.35 +0.10 (3.08%) Nov 27, 4:58 PM

Stock Price Chart

Key Info

Market Cap 12.83M
Revenue (ttm) n/a
Net Income (ttm) -17.11M
Shares Out 3.95M
EPS (ttm) -6.11
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day November 27
Last Price $3.25
Previous Close $3.04
Change ($) 0.21
Change (%) 6.91%
Day's Open 3.08
Day's Range 3.03 - 3.35
Day's Volume 308,844
52-Week Range 2.20 - 15.82

More Stats

Market Cap 12.83M
Enterprise Value n/a
Earnings Date (est) Mar 5, 2021
Ex-Dividend Date n/a
Shares Outstanding 3.95M
Float 3.60M
EPS (basic) -7.15
EPS (diluted) -6.11
FCF / Share -3.58
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 138,792
Short Ratio 0.47
Short % of Float 3.85%
Beta 1.02
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 0.68
Revenue n/a
Operating Income -16.29M
Net Income -17.11M
Free Cash Flow -14.13M
Net Cash 16.62M
Net Cash / Share 4.21
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -28.25%
ROE -96.24%
ROIC -389.60%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (3)

Buy 0
Overweight 0
Hold 3
Underweight 0
Sell 0

Analyst Consensus: Hold

Price Target

Current: $3.25
Target: 10.00
*Average 12-month price target from 1 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Operating Income-47.11-43.33-29.44-13.81-7.58-5.78
Net Income-47.60-43.54-28.91-13.36-7.18-6.50
Shares Outstanding33.7831.1917.6611.45--
Earnings Per Share-1.41-1.40-1.64-1.17-0.92-1.18
Operating Cash Flow-29.05-39.08-22.13-12.01-7.93-4.75
Capital Expenditures-0.92-4.67-4.99-0.48-1.38-0.08
Free Cash Flow-29.97-43.74-27.13-12.49-9.32-4.83
Cash & Equivalents10.0640.5855.2218.2930.747.82
Total Debt0.80-----
Net Cash / Debt9.2640.5855.2218.2930.747.82
Book Value11.5453.5558.8022.7035.539.48
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Intec Pharma Ltd.
Country Israel
Employees 38
CEO Jeffrey A. Meckler

Stock Information

Ticker Symbol NTEC
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: NTEC


Intec Pharma Ltd, a clinical stage biopharmaceutical company, focuses on developing drugs based on its proprietary Accordion Pill platform technology in Israel. Its Accordion Pill is an oral drug delivery system that is designed to enhance the efficacy and safety of existing drugs and drugs in development by utilizing a gastric retention and specific release mechanism. The company's lead product candidate is Accordion Pill Carbidopa/Levodopa, which is in a Phase III clinical trial for the treatment of Parkinson's disease symptoms in advanced Parkinson's disease patients. It is also developing Accordion Pill Zaleplon that is in a Phase III clinical trial as a treatment for the induction and maintenance of sleep in patients suffering from insomnia; a product candidate, which has completed a Phase I clinical trial for the prevention and treatment of gastroduodenal and small bowel Nonsteroidal Anti-Inflammatory Drug induced ulcers; and AP-CBD/THC, AP-THC, and AP-CBD product candidates with Cannabidiol and 9-Tetrahydrocannabinol for the treatment of various pain indications. Intec Pharma Ltd. has a research collaboration agreement with Merck to explore using the Accordion Pill platform for development program. The company was formerly known as Intec Pharmaceuticals (2000) Ltd. and changed its name to Intec Pharma Ltd in March 2004. Intec Pharma Ltd was founded in 2000 and is based in Jerusalem, Israel.